Table 1.
Patient and transplant characteristics
| Characteristics | n = 57 |
|---|---|
| Age (years), median (range) | 28 (12–58) |
| Sex | |
| Male | 28 (49%) |
| Female | 29 (51%) |
| Disease risk at transplant | |
| Standard-risk | 41 (72%) |
| High-risk | 16 (28%) |
| Disease | |
| Acute myelogenous leukemia | 31 (54%) |
| Acute lymphoblastic leukemia | 12 (21%) |
| Mixed lineage acute leukemia | 1 (1%) |
| Chronic myelogenous leukemia | 2 (4%) |
| Myelodysplastic syndrome | 6 (11%) |
| Malignant lymphoma | 5 (9%) |
| Conditioning regimen | |
| FLU/TBI | 26 (46%) |
| FLU/TBI/CY | 16 (28%) |
| FLU/TBI/THIO | 7 (12%) |
| FLU/TBI/MEL | 2 (4%) |
| TBI/CY/ATG | 3 (5%) |
| TBI/MEL/ATG | 3 (5%) |
| GVHD prophylaxis | |
| Tacrolimus + MMF | 35 (61%) |
| Cyclosporine + MMF | 22 (39%) |
| HLA matching | |
| 4/6 + 4/6 | 25 (44%) |
| 4/6 + 5/6 | 17 (29%) |
| 4/6 + 6/6 | 2 (4%) |
| 5/6 + 5/6 | 7 (12%) |
| 5/6 + 6/6 | 4 (7%) |
| 6/6 + 6/6 | 2 (4%) |
| Combined dose of cryopreserved TNC (×107/kg) | |
| Median (range) | 4.8 (2.8–10.1) |
Abbreviations: GVHD, graft-versus-host disease; TNC, total nucleated cells; FLU, fludarabine; TBI, total-body irradiation; CY, cyclophosphamide; THIO, thiotepa; MEL, melphalan; ATG, antithymocyte globulin; MMF, mycophenolate mofetil